Patents by Inventor Tsutomu Mimoto
Tsutomu Mimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7816387Abstract: The present invention relates to a compound of the formula (1): wherein R1 is group of the formula (2): (wherein X is nitrogen atom or C(R5), Y is nitrogen atom or C(R6), R5 and R6 are each independently hydrogen atom, etc.) etc., m is 1 to 6, L1 is single bond, etc., R2 is hydrogen atom, substituted or unsubstituted alkyl group, etc., R3 is hydrogen atom, etc., L2 is single bond, etc., R4 is hydrogen atom, substituted or unsubstituted aryl group, etc., or pharmaceutically acceptable salt thereof, being useful for preventing or treating Alzheimer's disease.Type: GrantFiled: August 31, 2006Date of Patent: October 19, 2010Assignees: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Tsutomu Mimoto, Satoshi Nojima, Naoya Kinomura, Yoshiaki Kiso
-
Publication number: 20090198056Abstract: The present invention relates to a compound of the formula (1): wherein R1 is group of the formula (2): (wherein X is nitrogen atom or C(R5), Y is nitrogen atom or C(R6), R5 and R6 are each independently hydrogen atom, etc.) etc., m is 1 to 6, L1 is single bond, etc., R2 is hydrogen atom, substituted or unsubstituted alkyl group, etc., R3 is hydrogen atom, etc., L2 is single bond, etc., R4 is hydrogen atom, substituted or unsubstituted aryl group, etc., or pharmaceutically acceptable salt thereof, being useful for preventing or treating Alzheimer's disease.Type: ApplicationFiled: August 31, 2006Publication date: August 6, 2009Inventors: Tsutomu Mimoto, Satoshi Nojima, Naoya Kinomura, Yoshiaki Kiso
-
Patent number: 6673772Abstract: A novel dipeptide compound inhibiting the enzymatic activity of HIV protease and an anti-AIDS medicine comprising this dipeptide compound as an effective component represented by formula (I) wherein R1, R2, and R3 independently represent C1-4 alkyl, alkoxyl, hydrogen etc . . . (provided that not all of the R1, R2, and R3 are hydrogen), R2 and R3 may form a ring together, R4 represents C1-4 alkyl or hydrogen; X is a methylene group or a sulfur atom; Y represents e.g., a five or six member monocycle or aryloxyalkyl having up to 12 carbon atoms (provided that the aromatic ring may be substituted by alkyl etc . . . ); and Z represents a C1-6 aliphatic hydrocarbon or an aromatic hydrocarbon having up to 12 carbon atoms (provided that this aromatic ring may be substituted by alkyl etc . . . , or at least one carbon atom in the aromatic hydrocarbon may be replaced by a hereto atom).Type: GrantFiled: August 27, 2001Date of Patent: January 6, 2004Assignee: Sumitomo Pharmaceuticals Company LimitedInventors: Tsutomu Mimoto, Keisuke Terashima, Haruso Takaku, Shinji Matsumoto, Makoto Shintani, Satoshi Nojima
-
Patent number: 6399568Abstract: A cyclic tetrapeptide derivative represented by the general formula (I): wherein: R11, R12, R21 and R22 independently denote a monovalent group selected from hydrogen, a linear or branched alkyl group with 6 or less carbon atoms, benzyl group, 4-methoxybenzyl group, 3-indolylmethyl group, (N-methoxy-3-indolyl) methyl group, (N-formyl-3-indolyl)methyl group, etc.; R3 denotes a divalent group selected from a linear chained hydrocarbon group with 3 or 4 carbon atoms, or the linear branched hydrocarbon group having a branched chain added to the chain, or a divalent group substituted with a heteroatom; R4 denotes a divalent chained hydrocarbon group with 4 to 6 carbon atoms, or a divalent group derived from said hydrocarbon group by addition etc.Type: GrantFiled: March 1, 2000Date of Patent: June 4, 2002Assignee: Japan Energy CorporationInventors: Norikazu Nishino, Minoru Yoshida, Sueharu Horinouchi, Yasuhiko Komatsu, Tsutomu Mimoto
-
Publication number: 20020049165Abstract: A novel dipeptide compound inhibiting the enzymatic activity of HIV protease, an anti-AIDS medicine comprising this dipeptide compound as an effective component.Type: ApplicationFiled: August 27, 2001Publication date: April 25, 2002Inventors: Tsutomu Mimoto, Keisuke Terashima, Haruso Takaku, Shinji Matsumoto, Makoto Shintani, Satoshi Nojima
-
Patent number: 6329502Abstract: &bgr;-Amino-&agr;-hydroxycarboxylic acid derivatives represented by the following formula and salts thereof which are useful as human immunodeficiency virus (HIV) protease inhibitors: The compounds are effective for treating a patient suffering from AIDS and AIDS related diseases.Type: GrantFiled: January 25, 1995Date of Patent: December 11, 2001Assignee: Japan Energy CorporationInventors: Tsutomu Mimoto, Naoko Hattori, Makoto Shintani, Yuuichi Nagano, Yoshiaki Kiso
-
Patent number: 6313094Abstract: &bgr;-Amino-&agr;-hydroxycarboxylic acid derivatives represented by the following formula and salts thereof which are useful as human immunodeficiency virus (HIV) protease inhibitors: The compounds are effective for treating a patient suffering from AIDS and AIDS related diseases.Type: GrantFiled: May 20, 1994Date of Patent: November 6, 2001Assignee: Japan Energy CorporationInventors: Tsutomu Mimoto, Naoko Hattori, Makoto Shintani, Yuuichi Nagano, Yoshiaki Kiso
-
Patent number: 6291432Abstract: A novel tripeptide compound represented by the following general formula (I) exhibiting superior HIV protease inhibition activity, and an anti-AIDS medicine comprising this compound as an effective component and a pharmaceutically acceptable salt thereof. (R)-N-(2-methylbenzyl)-3-{(2S,3S)-3-[N-(2-chromonecarbonyl)-L-asparaginyl]amino-2-hydroxy-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide can be given as a typical example of this compound.Type: GrantFiled: February 16, 1999Date of Patent: September 18, 2001Assignee: Japan Energy CorporationInventors: Haruo Takaku, Satoshi Nojima, Tsutomu Mimoto, Keisuke Terashima, Yoshiaki Kiso
-
Patent number: 6222043Abstract: The present invention provides synthetic methodology to produce novel dipeptide compounds and pharmaceutically acceptable salts thereof which exhibit excellent HIV protease inhibitory activity and excellent bioavailability from digestive tracts. Methods of using the dipeptide compounds and pharmaceutically acceptable salts thereof also are provided.Type: GrantFiled: January 8, 1999Date of Patent: April 24, 2001Assignee: Japan Energy CorporationInventors: Ryohei Kato, Tsutomu Mimoto, Tominaga Fukazawa, Naoko Morohashi, Yoshiaki Kiso
-
Patent number: 5962640Abstract: The present invention provides a novel dipeptide compound or pharmaceutically acceptable salt thereof which exhibits an excellent HIV protease inhibitory activity and an excellent bioavailability from digestive tracts, and an anti-AIDS agent comprising said dipeptide compound as an effective ingredient. ##STR1## (wherein R.sub.1 represents 5-membered or 6-membered monocyclic hydrocarbon group or heterocyclic group wherein more than one carbon atom of said monocyclic hydrocarbon group is substituted with hetero atom. X represents methylene group (--CH.sub.2 --), chloromethylene group(--CH(Cl)--), oxygen atom sulfur atom or sulfonyl group (--SO.sub.2 --). R.sub.21 and R.sub.22 each represents hydrogen atom or aliphatic hydrocarbon group having 1-6 carbons. R.sub.3 represents aliphatic hydrocarbon group or monovalent group derived from aromatic monocyclic hydrocarbon having 1-6 carbons.Type: GrantFiled: August 21, 1998Date of Patent: October 5, 1999Assignee: Japan Energy CorporationInventors: Ryohei Kato, Tsutomu Mimoto, Tominaga Fukazawa, Naoko Morohashi, Yoshiaki Kiso
-
Patent number: 5932550Abstract: The present invention provides a novel dipeptide compound or pharmaceutically acceptable salt thereof which exhibits an excellent HIV protease inhibitory activity and an excellent bioavailability from digestive tracts, and an anti-AIDS agent comprising said dipeptide compound as an effective ingredient.General formula (I): ##STR1## (wherein R.sub.1 represents 5-membered or 6-membered monocyclic hydrocarbon group or heterocyclic group wherein more than one carbon atom of said monocyclic hydrocarbon group is substituted with hetero atom. X represents methylene group (--CH.sub.2 --), chloromethylene group(--CH(Cl)--), oxygen atom sulfur atom or sulfonyl group (--SO.sub.2 --). R.sub.21 and R.sub.22 each represents hydrogen atom or aliphatic hydrocarbon group having 1-6 carbons. R.sub.3 represents aliphatic hydrocarbon group or monovalent group derived from aromatic monocyclic hydrocarbon having 1-6 carbons.Type: GrantFiled: June 26, 1996Date of Patent: August 3, 1999Assignee: Japan Energy CorporationInventors: Ryohei Kato, Tsutomu Mimoto, Tominaga Fukazawa, Naoko Morohashi, Yoshiaki Kiso
-
Patent number: 5644028Abstract: A process for producing peptide derivatives of formula (1) or salts thereof: ##STR1## which comprises condensation of peptide derivative of formula (2): ##STR2## with carboxylic acid of formula (3): ##STR3## or condensation of a peptide derivative of formula (4): ##STR4## with a protected amino acid of formula (5'): ##STR5## wherein R.sup.1 and R.sup.2 are a lower alkyl group or hydrogen atom, R.sup.3 is a lower alkyl group, X is a methylthiomethyl, methanesulfonylmethyl, carbamoylmethyl, or a lower alkyl group, Ar is an aryl or heteroaryl group, and A.sup.4 is Ar--O--CH.sub.2 --CO. The peptide derivatives and salts thereof are useful as the human immunodeficiency virus (HIV) protease inhibitors.Type: GrantFiled: December 28, 1994Date of Patent: July 1, 1997Assignee: Japan Energy CorporationInventors: Tsutomu Mimoto, Sumitsugu Kisanuki, Osamu Takahashi, Yoshiaki Kiso